Table 1 Clinical characteristics and laboratory results of patients evaluated for oral levodopa administration

From: Association of Enterococcus faecalis and tyrosine decarboxylase gene levels with levodopa pharmacokinetics in Parkinson’s disease

 

PD (n = 21)

Age, years

72.00 [68.00, 74.00]

Female/Male

12/9

Disease duration, years

7.00 [6.00, 9.00]

Hohen and Yahr stage

3.00 [3.00, 3.00]

Body weight, kg

54.40 [47.60, 61.60]

Body mass index, kg/m2

22.21 [18.59, 24.19]

Levodopa daily dose, mg/day

500.00 [350.00, 600.00]

Levodopa-equivalent daily dose, mg/day

693.00 [537.50, 865.00]

Anti-parkinsonian medication other than levodopa, n (%)

 Dopamine agonist

14 (66.7)

 COMT inhibitor

9 (42.9)

 MAO-B inhibitor

8 (38.1)

 Amantadine

5 (23.8)

 Istradefylline

3 (14.3)

 Zonisamide

11 (52.4)

 Trihexyphenidyl

3 (14.3)

Cmax of levodopa, μmol/L

9.12 [5.77, 10.47]

AUC of levodopa, μmol h/L

11.44 [8.43, 12.78]

Tmax of levodopa, min

45.00 [30.00, 60.00]

Cmax of carbidopa, μmol/L

0.24 [0.17, 0.32]

AUC of carbidopa, μmol h/L

0.45 [0.35, 0.71]

Tmax of carbidopa, min

120.00 [60.00, 120.00]

Cmax of levodopa/AUC of carbidopa

13.37 [11.79, 16.05]

AUC of levodopa/AUC of carbidopa

7.72 [6.88, 10.46]

Relative E. faecalis abundance

−21.88 [−24.86, −17.22]

Relative tyrDC gene abundance

−20.19 [−21.63, −18.08]

E. faecalis abundance (×10−7)

2.60 [0.33, 65.61]

tyrDC gene abundance (×10−7)

8.37 [3.08, 36.08]

  1. Values are presented as the median [interquartile range].
  2. AUC area under the plasma concentration-time curve, Cmax maximum plasma concentration, COMT catechol-O-methyl transferase, E. faecalis Enterococcus faecalis, MAO-B monoamine oxidase-B, PD Parkinson’s disease, Tmax, time to maximum concentration, tyrDC tyrosine decarboxylase.
Back to article page